摘要
目的:观察孟鲁司特钠联合沙美特罗治疗哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)患者的效果。方法:回顾性分析2020年1月至2023年6月该院收治的78例ACOS患者的临床资料,根据治疗方法不同将其分为研究组和对照组各39例。对照组采取沙美特罗治疗,研究组在对照组基础上联合孟鲁司特钠治疗,比较两组临床疗效、治疗前后肺功能指标[呼气峰值流速(PEF)、用力肺活量(FVC)、残气量/肺总量(RV/TLC)、深吸气量/肺总量(IC/TLC)、第1秒用力呼气容积(FEV_(1))]水平、炎性因子[γ干扰素(INF-γ)、白细胞介素-18(IL-18)]水平、症状[哮喘症状评分表(ACT)、慢性阻塞性肺疾病评分表(CAT)及呼吸困难评估量表(mMRC)]评分和治疗期间不良反应发生率。结果:研究组治疗总有效率为94.87%(37/39),高于对照组的76.92%(30/39),差异有统计学意义(P<0.05);治疗后,研究组PEF、FVC、IC/TLC、FEV_(1)水平均高于对照组,RV/TLC、INF-γ、IL-18水平均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组ACT评分高于对照组,CAT、mMRC评分均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:孟鲁司特钠联合沙美特罗治疗ACOS患者可提高治疗总有效率,改善肺功能指标水平和症状评分,降低炎性因子水平,效果优于单纯沙美特罗治疗。
Objective:To observe effects of Montelukast sodium combined with Salmeterol in treatment of patients with asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS).Methods:The clinical data of 78 patients with ACOS admitted to this hospital from January 2020 to June 2023 were retrospectively analyzed.According to different treatment methods,they were divided into study group and control group,39 cases in each.The control group was treated with Salmeterol,while the study group was treated with Montelukast sodium on the basis of that of the control group.The clinical efficacy,the pulmonary function indexes[peak expiratory flow(PEF),forced vital capacity(FVC),residual volume/total lung capacity(RV/TLC),inspiratory volume/total lung capacity(IC/TLC),forced expiratory volume in one second(FEV_(1))]levels,the inflammatory factors[interferon-γ(INF-γ),interleukin-18(IL-18)]levels,the symptoms[asthma control test(ACT),chronic obstructive pulmonary disease score(CAT)and dyspnea assessment scale(mMRC)]scores before and after the treatment,and the incidence of adverse reactions during the treatment were compared between the two groups.Results:The total effective rate of treatment in the study group was 94.87%(37/39),which was higher than 76.92%(30/39)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of PEF,FVC,IC/TLC and FEV_(1)in the study group were higher than those in the control group,the levels of RV/TLC,INF-γand IL-18 were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the ACT score of the study group was higher than that of the control group,the CAT and mMRC scores were lower than those of the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Montelukast sodium combined with Salmeterol in the treatment of the ACOS patients can impro
作者
李硕
LI Shuo(Department of Respiratory and Nephropathy of Kaifeng 155 Hospital,Kaifeng 475003 Henan,China)
出处
《中国民康医学》
2024年第2期28-30,34,共4页
Medical Journal of Chinese People’s Health
关键词
沙美特罗
孟鲁司特钠
哮喘-慢性阻塞性肺疾病重叠综合征
肺功能
炎性因子
症状
Salmeterol
Montelukast sodium
Asthma-chronic obstructive pulmonary disease overlap syndrome
Lung function
Inflammatory factor
Symptom
